On Friday, Shares of Sabre Corp (NASDAQ:SABR), gained 0.68% to $29.68.
Sabre Corporation and Hewlett Packard Enterprise, declared a multi-year renewal of their long-standing relationship.
Under the agreement, Hewlett Packard Enterprise will provide virtualization, automation and security services, hardware and software to support faster product development and extend Sabre’s position as the leading technology provider to the global travel industry. HPE also will provide new services to support Sabre’s growth and product priorities in the areas of data analysis, operations, e-commerce, retailing and merchandising for businesses across the travel industry.
“As the leading innovator to the global travel industry, Sabre is committed to delivering technology solutions to our customers based on world-class virtualization, security and operability,” said Tom Klein, Sabre president and CEO. “This agreement also delivers new capabilities to accelerate product development and improvement our speed-to-market, all driven by Sabre and supported by Hewlett Packard Enterprise.”
Hewlett Packard Enterprise has supported Sabre’s infrastructure and applications environments for more than 14 years, providing infrastructure services counting a portfolio of hosting and storage solutions. This expanded agreement leverages products and services from across Hewlett Packard Enterprise’s four transformation areas to assist Sabre maintain its leadership position.
Sabre Corporation provides technology solutions to the travel and tourism industry worldwide. It operates in two segments: Travel Network, and Airline and Hospitality Solutions. The Travel Network segment operates a business-to-business travel marketplace that offers travel content, such as inventory, prices, and availability from a range of travel suppliers, counting airlines, hotels, car rental brands, rail carriers, cruise lines, and tour operators, with a network of travel buyers comprising online and offline travel agencies, travel administration companies, and corporate travel departments.
Shares of Ascena Retail Group Inc (NASDAQ:ASNA), inclined 0.51% to $11.86, during its last trading session.
ascena retail group, declares the release of its Fiscal 2016 first quarter financial results will take place on Tuesday, December 1, 2015. Results will be released over Business Wire at about 4:00 PM Eastern Time. The company will also host a conference call at 4:30 PM Eastern Time to review its results, which will comprise comments by David Jaffe, President & CEO, and Robb Giammatteo, Executive Vice President & CFO, followed by a question and answer session.
Ascena Retail Group, Inc., through its auxiliaries, operates as a specialty retailer of clothing, shoes, and accessories for missy, plus-size women, and tween girls in the United States, Canada, and Puerto Rico.
Finally, Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL), ended its last trade with 8.70% gain, and closed at $6.00.
Anavex Life Sciences Corp., declares that Kristina M. Capiak, CCRP has been promoted the Company’s Vice President of Regulatory Affairs. She is overseeing U.S. and international regulatory matters for Anavex, counting filings and interactions with the FDA and other regulatory authorities.
“We are excited to expand Ms. Capiak’s role to oversee the Company’s clinical development programs and other indications given Ms. Capiak’s expertise and we are delighted to have her on our team,” said Dr. Christopher U. Missling, PhD, President and Chief Executive Officer for Anavex.
Ms. Capiak has more than 10 years of academic clinical research and healthcare industry experience within the biotech industry. Priority to joining Anavex, Ms. Capiak was the Global Regulatory Lead at Retrophin, Inc. where she implemented U.S. and EU strategy for the ongoing development programs, which received orphan drug designations in addition to fast track designation. At Regeneron Pharmaceuticals Ms. Capiak was on the pharmacovigilance and risk administration team where she analyzed the ongoing safety events for the pipeline of development products and for EYLEA®.
Anavex Life Sciences Corp., a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of Alzheimer’s disease, central nervous system diseases, and pain and various cancers.